Previous close | 3.7400 |
Open | 3.8200 |
Bid | 3.9300 x 300 |
Ask | 3.9800 x 100 |
Day's range | 3.7100 - 4.0100 |
52-week range | 2.0100 - 6.1300 |
Volume | |
Avg. volume | 990,300 |
Market cap | 322.153M |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.7800 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.89 |
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in follow up – SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today
The analysts covering Sutro Biopharma, Inc. ( NASDAQ:STRO ) delivered a dose of negativity to shareholders today, by...